Showing posts with label Trials and Studies. Show all posts
Showing posts with label Trials and Studies. Show all posts

Friday, January 14, 2011

New Clinical Trial Information: Imetelstat Sodium Telemerase Inhibitor

Trial Information: 45 young patients will be recruited for a Phase I study of the new telemerase inhibitor imetelstat. Patients must be under 21 years old and have any solid tumor or lymphoma cancer, except for brain tumors or metastases. They must have relapsed or been resistant (refractory) to previous retreatment.


Thursday, January 13, 2011

New Clinical Trial Information: Lucatumumab + Bendamustine

Trial Information: 50 patients are being recruited for a Phase I trial of the new anti-CD40 monoclonal antibody lucatumumab (aka HCD122). Patients must have follicular lymphoma and have become resistant to rituximab following previous therapy. Patients will be given combination therapy of lucatumumab with bendamustine, a relatively new alkylating agent.


Wednesday, January 12, 2011

How Clinical Trials Work

A clinical trial is the standard tool of scientific, evidence-based medicine for determining the safety and effectiveness of new drugs and drug combinations, including for cancer therapy.

The basic appeal of clinical trials for patients is the ability to gain access to potentially powerful new drugs which are not yet approved and may be unavailable in hospitals or clinics for years. However, consent to participate in a clinical trial should never be given lightly. As a patient, you need to be aware of the objectives of the trial, basic information about the drug, how likely the trial's researchers believe you might benefit from what they want to put into your body, and what the potential side effects and negative consequences of treatment might be.


New Drug Information: Lucatumumab Anti-CD40 Monoclonal Antibody

Also known as: HCD122

Drug Information: Lucatumumab is one of several experimental anti-CD40 monoclonal antibodies. CD40 is a cellular surface protein involved in immune system signaling, which is present on cancerous B cells. The drug's developer, Novartis, believes that it both blocks proliferation of malignant cells and attracts other immune system cells to attack the cancer. It is given intravenously on a weekly basis for multi-week treatment cycles.

Friday, January 7, 2011

95% of Statistics are Bogus (Including This One)

My own Statistics page still languishes in its unstarted state, but a new article in Science News manages to present, more or less in layman's terms, precisely the sorts of problems that I wanted to highlight for readers here. So in the meantime, it's a useful starting point.

Tom Siegfried explains very well that the scientific method and statistical analysis are not necessarily natural bed-partners, and that even the games we play to make statistics seem "reliable" can end up, in certain cases, actually making them more misleading. Most of this will be old news to people with stats training, but it's still a good refresher. There's also a section specifically on the problems inherent in clinical trials:
Statistical problems also afflict the “gold standard” for medical research, the randomized, controlled clinical trials that test drugs for their ability to cure or their power to harm. Such trials assign patients at random to receive either the substance being tested or a placebo, typically a sugar pill; random selection supposedly guarantees that patients’ personal characteristics won’t bias the choice of who gets the actual treatment. But in practice, selection biases may still occur, Vance Berger and Sherri Weinstein noted in 2004 in Controlled Clinical Trials. “Some of the benefits ascribed to randomization, for example that it eliminates all selection bias, can better be described as fantasy than reality,” they wrote.

Thursday, January 6, 2011

Clinical Trial Information: RO4929097 Gamma-Secretase Inhibitor

Trial Information: 40 patients are being recruited for a Phase I study of the experimental new gamma-secretase inhibitor RO4929097 in combination with capecitabine, an oral DNA synthesis inhibitor already used in colon cancer and breast cancer. Eligible patients include those with any metastatic solid tumor cancer or lymphoma.

Clinical Trial Information: AEG35156

Trial Information: 51 patients are being recruited for a Phase I/II trial of the XIAP antisense AEG35156 in indolent lymphomas (including follicular lymphoma) and chronic lymphocytic leukemia (CLL). Patients must meet criteria for third-line treatment (or beyond) to enter the trial.

Wednesday, January 5, 2011

New Clinical Trial Information: GA101 Monotherapy

Trial Information: 180 patients with relapsed indolent lymphoma, including follicular lymphoma, will be recruited to test GA101 (aka RO5072759) monotherapy. Although this is a Phase II trial, patients will be randomized to receive either GA101 monotherapy or rituximab monotherapy.

New Drug Information: Galiximab

Drug Information: Galiximab is a chimeric human-macaque anti-CD80 monoclonal antibody which targets B-cells, including malignant cells. Blocking this site with antibodies appears to produce a range of anti-cancer effects. It is taken intravenously, weekly for four weeks.

New Drug Information: Bortezomib

Also known as: Velcade

Drug Information: Bortezomib is a proteasome inhibitor, a type of drug which targets structures inside the cell responsible for breaking down proteins. It has been theorized that cancerous cells are particularly vulnerable to this sort of induced dysfunction. It is typically given twice-weekly; weekly regimens were attempted in trials, and had fewer side effects but limited response rates.

New Drug Information: Ocrelizumab

Drug Information: Ocrelizumab is a fully human anti-CD20 monoclonal antibody which in preclinical studies was more powerful than rituximab. It is taken intravenously.

New Drug Information: Vorinostat Histone Deacetylase Inhibitor

Also known as: Zolinza, suberoylanilide hydroxamic acid


Drug Information: Vorinostat is a new histone deacetylase inhibitor, a class of drugs that block specific enzymes and appear to have some role in suppressing malignant activity on the intracellular level. In the trial setting for indolent lymphoma, vorinostat has been taken orally, daily.

Tuesday, January 4, 2011

Clinical Trial Information: GA-101 and Bendamustine

Trial Information: This is a Phase III trial recruiting 360 Canadian and American patients with indolent lymphoma, including follicular lymphoma, who have been previously treated and are refractory to rituximab. Patients will be randomized to receive bendamustine monotherapy or bendamustine with GA-101 (B-G).

Sunday, January 2, 2011

New Clinical Trial Information: Ofatumumab + Bendamustine

Trial Information: This is an international Phase III trial of ofatumumab. 338 patients with relapsed or refractory indolent lymphoma, including follicular lymphoma, will be randomized to receive either bendamustine monotherapy or ofatumumab plus bendamustine (O-B), in eight 21-day cycles.

Clinical Trial Information: Bendamustine-Rituximab (B-R) (BRIGHT Study)

Trial Information: 436 patients will be randomized to receive either Bendamustine-Rituximab (B-R), or conventional therapy (R-CHOP or R-CVP). This is an international Phase III trial intended to compare the effectiveness of bendamustine with a conventional alkalating agent/anthracycline-based regimen, CHOP (cyclophosphamide, vincristine, prednisone, and doxorubicin) or CVP (cyclophosphamide, vincristine, and prednisone).

This study is recruiting people with follicular lymphoma, mantle call lymphoma, Waldenstrom macroglobulinemia, and marginal zone B-cell lymphomas. This is for patients eligible for first-line treatment, i.e. previously untreated and having one or more criteria for treatment (B symptoms, bulky disease, etc.).

Saturday, January 1, 2011

Clinical Trial Information: Ofatumumab in Older Patients

Trial Information: 37 patients over 70 years old are being recruited for a Phase II study of ofatumumab (Arzerra). Patients will be given weekly ofatumumab for eight weeks.

Eligible patients must have indolent lymphoma (follicular lymphoma or marginal zone lymphoma) and be previously untreated.


Thursday, December 30, 2010

Clinical Trial Information: Ofatumumab versus Rituximab

Trial Information: This is a Phase III comparative clinical trial of rituximab (Rituxan) and ofatumumab (Arzerra) monotherapy in follicular lymphoma patients who have relapsed following prior therapy with rituximab. 516 patients will be recruited and randomized to rituximab or ofatumumab, in both cases four weekly treatments followed by an additional treatment every two months, for eight months. Patients must have relapsed following a prior chemotherapy regimen that included rituximab.

Friday, December 24, 2010

Clinical Trial Information: Inotuzumab Ozogamicin

Trial Information: A Phase I trial recruiting patients with all types of B-cell non-Hodgkin's lymphoma, including follicular lymphoma. Patients will be randomized to receive varying dosages of inotuzumab ozogamicin with rituximab, cyclophosphamide, vincristine and prednisone (R-CVP), or with rituximab, gemcitabine, dexamethasone, and cisplatinum (R-GDP). Open only to people with relapsed disease.

Background Information: Inotuzumab ozogamicine is a potentially powerful new anti-CD22 monoclonal antibody, targeting a surface protein different than of rituximab and related anti-CD20 monoclonal antibodies.

In early trials, inotuzumab showed particular promise in follicular lymphoma patients. A Japanese Phase I trial of 13 follicular lymphoma patients produced a response in 11 patients (85%), with 7 patients (54%) achieving complete remission. The new trial evaluates inotuzumab as part of combination therapy, where results may be even more striking.

Canadian Locations: Edmonton, AB; Halifax, NS; Quebec City, QC.

For more information, see ClinicalTrials.gov.

Tuesday, December 21, 2010

Inotuzumab Ozogamicin: Next-Generation Antibody for Follicular Lymphoma

The success of rituximab, Bexxar, and Zevalin has spawned an entire industry of monoclonal antibody research in the treatment of follicular lymphoma and related diseases. Some of the most novel of these follow Bexxar and Zevalin in combining the antibody with a useful pharmaceutical payload.

How Inotuzumab Works: Inotuzumab is an anti-CD22 antibody, attacking a different protein than the more established drugs (which mostly target CD20). Inotuzumab itself is a humanized antibody, which carries a calicheamicin antibiotic. Once the antibody binds to the cell, the antibiotic is released into the cell and kills it. Calicheamicin is one of the most powerful anti-cancer agents in our experimental arsenal today; what is lacking, outside of drug candidates like this one, is an effective way to deliver it to the target.

Like rituximab, inotuzumab targets only B cells in the immune system, meaning it can be delivered in potent amounts against cancer without the systemic side effects of older chemotherapy drugs.

Drug Status: Currently in trials.


Side Effects: Almost all patients have reduced white blood cell counts. Three-quarters also suffer from anorexia and nausea.


Response Rates: In an impressive Japanese study reported in early 2010, 13 follicular lymphoma patients who had failed previous rituximab-based therapies were given IV inotozumab daily for 28 days. Despite the fact this population was heavily pre-treated, there was an 85% response rate, including seven complete remissions (54%).

Published Studies

Michinori Ogura et al. "Phase I Study of Inotuzumab Ozogamicin (CMC-544)." Cancer Science (2010).

Clinical Trial Information: Novitoclax (ABT-263)

Trial Information: A Phase I/Phase II study which began in 2006 seeks to enroll 98 lymphoma patients to study a new Bcl-2 inhibitor, navitoclax. Patients must have relapsed disease. The Phase I component will measure dosage in multiple types of lymphoma. The Phase II component will measure responses in follicular lymphoma and mantle cell lymphoma. Navitoclax is a daily, orally taken solution.

Background Information: An initial Phase I trial showed a 22% response rate across multiple types of lymphoma, with the majority of patients suffering side effects such as anemia, infections, diarrhea, nausea, and fatigue.

A second Phase I trial combined navitoclax with rituximab in untreated patients, resulting in a 67% response rate. In 11 follicular lymphoma patients, there were 4 complete remissions and 1 partial response.

Canadian Locations: Cross Cancer Institute (Edmonton, AB)

For more information, see ClinicalTrials.gov (#NCT00406809).